COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
05/03/2026
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of [...]
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI [...]
ArriVent BioPharma Reports Full Year 2025 Financial Results
05/03/2026
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underway [...]
Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
President & CEO Letter to Shareholders
05/03/2026
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 05, 2026 (GLOBE NEWSWIRE) -- Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
05/03/2026
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
CooperCompanies Announces First Quarter 2026 Results
05/03/2026
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First [...]
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
05/03/2026
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
05/03/2026
Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of [...]
Amneal to Participate in Upcoming Investor Conference
05/03/2026
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following [...]
MannKind Announces Settlement of Convertible Senior Notes
05/03/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
05/03/2026
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than [...]
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
05/03/2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS) Oral presentation on updated KYSA-6 Phase 2 data in generalized myasthenia gravis (gMG) [...]
Omada Health Announces GLP-1 Flex Care, Giving Employers a New, Flexible Path to Support Obesity Care
05/03/2026
Through Omada’s GLP-1 Flex Care offering, employers gain a new flexible option to connect employees with anti-obesity medication, virtual care, and lifestyle support SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) -- [...]
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
05/03/2026
PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company that [...]
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
05/03/2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical [...]
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
05/03/2026
Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year [...]
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
05/03/2026
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug [...]

Pages